ACCESS Newswire·Oct 9, 2025, 7:30 AM ET

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

TELO

Telomir Pharmaceuticals announced new preclinical findings that Telomir-1 shuts down cellular energy pathways & mitochondrial function in aggressive triple-negative breast cancer (TNBC) cells.
The drug induces cell death through iron-dependent regulation, causing a dose-dependent reduction in cancer cell viability in laboratory studies.
Adding iron back to the system reversed the drug's effects, confirming that Telomir-1's activity relies on disrupting cellular iron & energy balance.
Telomir-1 appears to exploit a metabolic weakness in TNBC cells by targeting iron-dependent enzymes called Jumonji domain histone demethylases (KDMs), specifically KDM5A/B & KDM6B.
The compound resets abnormal DNA methylation patterns to restore balanced gene expression, potentially sparing healthy tissue due to differences in iron management.
CEO Erez Aminov stated the findings represent an important step toward developing therapies for patients with limited treatment options.
Chief Scientific Advisor Dr. Angel confirmed the drug acts as a key regulator through specific biological pathways rather than nonspecific toxicity.
Telomir plans to expand research to pancreatic & leukemia models while conducting further animal studies in preparation for an Investigational New Drug (IND) submission.
TNBC accounts for 10-15% of breast cancer cases, lacks hormone & HER2 receptors, & has a five-year survival rate of only 12-15% for metastatic patients.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapies targeting epigenetic drivers of cancer, aging, & age-related diseases.